Press Release

FOR IMMEDIATE RELEASE

Cambridge-based tech-bio company transforming drug discovery with

explainable AI platform

World-leading bio and AI team is developing methodology to accelerate

high-confidence target discovery

Cambridge, UK – January 14, 2026 – Acuity Technologies Ltd today announced that it is developing its transformative drug discovery platform with world-leading researchers at the University of Cambridge.

This distinctive team is led in Biology by Professor David Rubinsztein, Professor of Molecular Neurogenetics at the University of Cambridge, working with two pioneers in explainable AI. This is backed by a board with government, medical and industrial experience and veteran corporate management with successful exits.

There is a lack of good quality target diversity for therapeutic development addressing major diseases. Acuity is tackling this by combining cutting-edge biology and AI expertise to realise AI's true potential in discovering therapeutic targets.

Acuity aims to develop a proprietary platform that can deliver substantial cost and time savings, potentially saving billions in downstream clinical failures resulting from poor target identification.

Initial applications focus on important pathways in neurodegeneration and oncology, including ferroptosis and autophagy mechanisms.

Professor David Rubinsztein said “our main aim is to accelerate therapies for patients by harnessing all available technologies”.

The end goal promises a system able to scale across different biologies and diseases, where target validation remains a critical bottleneck.

Contact: enquiries@acuity-technologies.com